Treatment with PRDX1 inhibitor showed that PRDX1 inhibition restrain the growth and metastasis of ccRCC.<h4>Conclusion</h4>In summary, the findings of this study revealed a novel role of PRDX1 in triggering ccRCC progression by inducing the phosphorylation of EGFR, supporting that PRDX1 may serve as a potential therapeutic target for the clinical management of ccRCC. This evidence concerns the gene EGFR and nonpapillary renal cell carcinoma.